Actionable news
All posts from Actionable news
Actionable news in GSK: GLAXOSMITHKLINE PLC,

the Securities Exchange Act of 1934

980 Great West Road, Brentford, Middlesex, TW8 9GS

Indicate by check mark whether the registrant files or

Form 20-F x Form 40-F

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

GlaxoSmithKline plc (the "Company")

Director Shareholding

Further to the announcement made by the Company on 8 November 2017, in respect of the appointment of Dr Hal Barron as Chief Scientific Officer and President, R&D, and Executive Director, Dr Barron assumed his new role on 1 January 2018.

As at the date of his appointment to the Board, Dr Barron held 1,644 American Depositary Shares in the Company.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.